Clinical Trials
5 trialsNCT02678572 2023-12-21
FOCUS
Delcath Systems Inc.
Phase 3 Completed
NCT05022901 2023-12-21
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Delcath Systems Inc.
Phase 3 Active not recruiting
NCT00324727 2021-06-21
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
Delcath Systems Inc.
Phase 3 Completed
NCT00003789 2013-07-16
Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
National Cancer Institute (NCI)
Phase 3 Completed
NCT00001296 2008-03-04
A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma
National Institutes of Health Clinical Center (CC)
Phase 3 Completed